China National Medicines Corporation (600511.SH) announced its semi-annual report for 2024, with revenue of 24.757 billion yuan, a year-on-year growth of 2.55%; net income attributable to shareholders of the listed company was 1.001 billion yuan, a year-on-year growth of 1.62%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 1.003 billion yuan, a year-on-year growth of 5.46%; basic earnings per share was 1.3261 yuan.
The company's main business is medical distribution. With the gradual deepening of healthcare reform, the emergence of pharmaceutical policies, and the stable development of regional healthcare diagnosis and treatment, the company seizes market opportunities, deepens innovative services, adheres to management and control for efficiency and compliance development. During the reporting period, the company's core business maintained stable growth, with steady increase in revenue from the main business and net profit.
The company has achieved 100% coverage of Beijing and other high-level hospitals, and covers over 4,700 primary healthcare institutions. Among them, the company's sales in second and third-tier hospitals rank first in the region, with strong coverage and service capabilities in the medical terminals of Beijing area. The company's retail direct sales business has covered the top 500 chain pharmacies and many individual pharmacies nationwide, with a direct distribution channel covering over 0.03 million stores, and an extended channel that can cover over 0.22 million terminal pharmacies. The company continues to strengthen cooperation with retail chains, create new retail service models, shorten the pharmaceutical distribution process, help brand pharmaceutical companies penetrate retail terminals, and achieve regional targeted marketing.